Exelixis (EXEL) And The Valuation Case For Its Cabometyx Growth Story

Exelixis stock performance snapshot after recent trading

Exelixis (EXEL) stock recently closed at US$54.55, with short term returns that have shifted over the past week and month. Investors may be reassessing the oncology company’s value score of 5 and intrinsic discount of 70%.

See our latest analysis for Exelixis.

Over the past year, Exelixis has combined short term share price momentum with stronger long term gains, with a year to date share price return of 25.17% and a 1 year total shareholder return of 43.93%. Recent moves indicate that investors are weighing oncology pipeline progress and perceived risks against the current 70% intrinsic discount and value score of 5.

If you are comparing Exelixis with other healthcare focused opportunities, this is a good moment to see what else is on the move through the 40 healthcare AI stocks.

Bulls see Exelixis as a discounted oncology specialist with a broad pipeline, while bears point to the small value score and price near the analyst target. Which side does the valuation work favour next?

Most Popular Narrative: 3% Overvalued

The most followed Exelixis narrative pegs fair value at $53, slightly below the recent $54.55 close, which sets up a tight valuation debate.

The recent introduction and rapid uptake of CABOMETYX in neuroendocrine tumors, combined with its continued strength and market leadership in renal cell carcinoma, signals an expanding patient base in tumor types with high unmet need. This is positioned to support ongoing revenue generation as aging populations and rising cancer incidence influence long term demand for oncology therapeutics.

Read the complete narrative.

Want to see what is baked into that $53 fair value for Exelixis? The narrative focuses on revenue trends, margin dynamics, and a leaner share count. Curious how those elements relate to the current analyst forecast path and the implied earnings profile by the end of the decade?

Result: Fair Value of $53 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Exelixis still faces key tests, including heavy reliance on cabozantinib and uncertainty around whether zanzalintinib will deliver enough to offset future patent and competition pressure.

Find out about the key risks to this Exelixis narrative.

Another view on Exelixis valuation

The first narrative framed Exelixis as about 3% overvalued at $53. A different lens tells another story. Using the SWS DCF model, Exelixis at $54.55 is compared with an estimated future cash flow value of $184.51, which screens as heavily undervalued. Which signal do you trust more?

Our DCF model is only as useful as the assumptions behind it, so it helps to see exactly how the cash flows and discount rate drive that gap, then decide whether those inputs fit your own view of Exelixis. Look into how the SWS DCF model arrives at its fair value.

Next Steps

After weighing these mixed signals around Exelixis, it helps to move quickly and check the underlying data for yourself so your view is grounded in facts. A simple next step is to review the 4 key rewards

Looking for more investment ideas beyond Exelixis?

If Exelixis has sharpened your focus, do not stop here. The right watchlist often comes from comparing a few strong but very different ideas side by side.

• Target dependable cash generators by reviewing companies screened for financial resilience and low downside risk through the 74 resilient stocks with low risk scores.
• Hunt for quality at a fair price by checking stocks that combine proven fundamentals with attractive pricing using the 49 high quality undervalued stocks.
• Spot opportunities the crowd may be missing by scanning the screener containing 18 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com